Deborah Zihler
Papers
1
Total Citations
32
H-Index
1
About
Deborah Zihler is a clinical researcher whose work centers on improving outcomes for patients with muscle-invasive urothelial carcinoma (MIUC), a high-risk bladder cancer. Her primary contributions lie in perioperative oncology, specifically investigating the integration of immunotherapy with standard chemotherapy to reduce high relapse rates. Zihler’s most cited work, a preplanned interim analysis of the SAKK 06/17 phase II trial (32 citations), explores the combination of durvalumab with cisplatin/gemcitabine before surgery. This study is notable for testing a novel chemoimmunotherapy approach in the neoadjuvant setting, aiming to enhance pathological complete response rates and long-term survival. By focusing on this challenging patient population, Zihler contributes to the evolving paradigm of combining immune checkpoint inhibitors with cytotoxic therapy, a strategy that could redefine standard care. Her research, though early-stage, addresses a critical unmet need, demonstrating her commitment to translating promising immunological insights into tangible clinical benefits for patients with aggressive urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1